Infliximab

英夫利西单抗

Report date: 2026/04/28 20:00:22

Base Information

Drug NameInfliximab
Drug Alias NameInfliximabum因福利美cA2英夫利昔单抗英利昔单抗 +[10] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsPlaque psoriasisDiabetic macular oedemaPediatric ulcerative colitis +[43] 
Global Approved IndicationsCrohn DiseaseArthritis, RheumatoidSpondylitis, Ankylosing +[4] 
Approved Indications in ChinaCrohn DiseaseArthritis, RheumatoidSpondylitis, Ankylosing
Original Approved Country/TerritoryUnited States
Original Approved Date1998/08/24
Country/TerritoryCzechiaBelgiumCanada +[23] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesJohnson & Johnson Innovative Medicine
China Registration ClassN/A

Develop Information

Active CompaniesJohnson & Johnson Innovative MedicineUniversity Of California San FranciscoUniversity Of Liverpool +[10] 
Inactive CompaniesJanssen Korea, Ltd., KoreaSchering-PloughUniversity of Athens +[26] 
Active IndicationsPlaque psoriasisPsoriasisMucocutaneous Lymph Node Syndrome +[17] 
Inactive IndicationsDiabetic macular oedemaPediatric ulcerative colitisCoronavirus Disease 2019 (COVID-19) +[26] 

Other Information

ATC CodeL04AB02
Related LinksWikipediaDrugBankKEGG